From its inception, the PVRI is concerned with enhancing the understanding of the complex pulmonary vascular diseases (PVDs). There are three key primary objectives of the institution: to improve the care of patients all over the world, who suffer from PVDs, to facilitate and accelerate research in the clinical and basic science of the PVDs, and to encourage the development of new therapies for PVDs. Through constant improvement, the PVRI has evolved to best achieve its primary objectives. The improved PVRI website and the new logo of the PVRI are the clear evidences of the phenotypic evolution of the PVRI. The changes in the core of the PVRI such as the new PVRI Constitution and organizational structure, the new Committee for Young Clinicians & Scientists, previously known as the “PVRI Young Council”, and establishment of new PVRI Task Forces are some of the aspects of genotypic evolution.
From the beginning of this year, through various meetings, discussions and interviews at the 8th PVRI Annual World Congress, the PVRI has come one step closer in better understanding the pathogenesis of PVDs and significant improvements of the current therapies. Drs. Oleg Pak and Djuro Kosanovic have summarized the activities of the 8th PVRI Annual World Congress in the PVRI News and Activities section. Bringing together basic scientists and clinicians investigating the molecular mechanisms behind the pathobiology of pulmonary vascular disease is of utmost importance as it applies to better understanding of the disease and more importantly to find new and effective therapeutics for the PVDs. The establishment of a new PVRI Task Force, Preclinical and Molecular Science, led by Prof. Mandy MacLean- an eminent scholar in the field of PVDs - is an excellent example of PVRI stepping forward in enhancing the understanding of PVDs.
The PVRI together with the Saudi Association for Pulmonary Hypertension (SAPH) at the 8th Annual Joint Pulmonary Hypertension Assembly further augmented our understanding of PVDs by elaborately discussing CTEPH, PH in the young, PAH in congenital heart diseases, management challenges in PAH patients and pregnancy challenges in PH patients as well as practical clinical scenarios and more specific PAH management updates & challenges and PH in the developing world: Diagnostic and Management Dilemmas. These discussions are available online as a part of our learning section on the PVRI website. To fight a complex disorder like PVDs, a collective effort in understanding the disease pathology and the potential therapeutic options is important. Therefore, PVRI has brought together the pharmaceutical industries, regulatory authorities, clinicians and basic scientists under one umbrella for the second time during the Annual Drug Discovery and Development Symposium in London.
The PVRI has moved further towards advancing the understanding of PVD through its Central Asia Task Force, now referred to as “CAPH”. (Central Asia Pulmonary Hypertension) This is facilitated by Drs. Stefano Ghio from Italy, Majdy Idrees and Tarek Kashour from Saudi Arabia and Ghazwan Butrous from the UK, who held the first successful Master Class on PVD. PVRI successfully conducted theoretical and practical sessions on echocardiography and right heart catheterization. Dr. Stefano Ghio conducted an Echo/Doppler examination on patients with suspected pulmonary hypertension and right heart catheterization was conducted under the supervision and instruction of Dr. Tarek Kashour. Apart from educational and clinical activities, PVRI also held its first fundraising event, the PVRI Charity Concert, in Canterbury, United Kingdom on May 5th 2015, in honor of “World Pulmonary Hypertension Day”. Over 200 people attended the concert, and the PVRI was successful in raising close to £12,000 (= $18,250).
The PVRI Chronicle, as a brand ambassador of PVRI, is upholding the Institute’s mission statement by focusing on the traditional triad of research, education, and clinical care, in activity and report alike, presents you with news and activities from PVRI to interactive discussions and case reports in the field of PVDs. This issue includes an interview with Prof. Ghazwan Butrous, in which he summarizes pulmonary vascular disease in the early days and the birth of the PVRI, Prof. Ghazwan says that “..science is a collaborative work- so you obviously like to work with other centers and scientists and exchange ideas…” but he felt the lack of a forum for collaborative work in particular to pulmonary vascular disease and this void lead to the birth of the PVRI. For the Journal club section, we have selected two interactive discussions covering dysregulated inflammatory response in pulmonary hypertension and dietary L-carnitine: a strategy to combat COPD-induced muscle wasting. The Learners’ Corner presents a review article on advances in understanding of pulmonary arterial hypertension and the evolution of experimental pulmonary hypertension models; a perspective on the study of high altitude pulmonary arterial hypertension at the Chilean Andean Altiplano and a ‘Did You Know’ article on pulmonary edema. The Clinical Corner presents an interesting case report on chronic thromboembolic pulmonary hypertension in a young patient.
Taken together, with the new changes and the collective effort of PVRI fellows, we are clearly one step closer to enhancing our understanding of pulmonary vascular disease which comprises of: improving the care of pulmonary vascular disease patients, facilitating and accelerating research in the clinical and basic science of the disease, and encouraging the development of new therapies.